<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">445326328</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180317142722.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170323e20110301xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s10989-011-9239-y</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s10989-011-9239-y</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Tripeptides with C-Terminal Arginine as Potential Inhibitors of Urokinase</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Agnieszka Markowska, Irena Bruzgo, Wojciech Miltyk, Krystyna Midura-Nowaczek]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">We synthesized and tested ten peptides with the molecular structure being H-d-Ser-AA-Arg-OH for their effect on the amidolytic activities against urokinase, thrombin, trypsin, plasmin, tissue plasminogen activator and kallikrein. The inserted amino acid in each peptide was either leucine, norleucine, izoleucine, valine, norvaline, α-metyloalanine, α-aminobutanoic acid, homoleucine, tert-leucine or neoglycine. H-d-Ser-NVal-Arg-OH (compound 4) was the most active inhibitor of urokinase plasminogen activator with a Ki value of 0.85μM. Compound 4 showed cytotoxic effect against MDA-MB-231 and DLD cell lines, respectively, with IC50 values of 25 and 19μM. Synthesised compounds did not have activity against MCF-7 cancer cells. These peptides were nontoxic against pig's erythrocytes in vitro.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer Science+Business Media, LLC, 2011</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Urokinase inhibitor</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Anti-amidolytic activity</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Low molecular weight peptides</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Markowska</subfield>
   <subfield code="D">Agnieszka</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Bruzgo</subfield>
   <subfield code="D">Irena</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Miltyk</subfield>
   <subfield code="D">Wojciech</subfield>
   <subfield code="u">Laboratory of Drug Analysis, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Midura-Nowaczek</subfield>
   <subfield code="D">Krystyna</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">International Journal of Peptide Research and Therapeutics</subfield>
   <subfield code="d">Springer Netherlands</subfield>
   <subfield code="g">17/1(2011-03-01), 47-52</subfield>
   <subfield code="x">1573-3149</subfield>
   <subfield code="q">17:1&lt;47</subfield>
   <subfield code="1">2011</subfield>
   <subfield code="2">17</subfield>
   <subfield code="o">10989</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s10989-011-9239-y</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">brief-communication</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s10989-011-9239-y</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Markowska</subfield>
   <subfield code="D">Agnieszka</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Bruzgo</subfield>
   <subfield code="D">Irena</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Miltyk</subfield>
   <subfield code="D">Wojciech</subfield>
   <subfield code="u">Laboratory of Drug Analysis, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Midura-Nowaczek</subfield>
   <subfield code="D">Krystyna</subfield>
   <subfield code="u">Department of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">International Journal of Peptide Research and Therapeutics</subfield>
   <subfield code="d">Springer Netherlands</subfield>
   <subfield code="g">17/1(2011-03-01), 47-52</subfield>
   <subfield code="x">1573-3149</subfield>
   <subfield code="q">17:1&lt;47</subfield>
   <subfield code="1">2011</subfield>
   <subfield code="2">17</subfield>
   <subfield code="o">10989</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
